Selective sigma-1 receptor antagonists for the treatment of pain

Future Medicinal Chemistry

Volumn 6, Issue 10, 2014, Pages 1179-1199

  Almansa, Carmen ^a   Vela, José Miguel ^a  

^a Esteve   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE ANTAGONIST; SIGMA 1 OPIATE RECEPTOR; SIGMA 1 RECEPTOR ANTAGONIST; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG; ANALGESIC AGENT; SIGMA-1 RECEPTOR;

ANTINOCICEPTION; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CELL MEMBRANE; DRUG IDENTIFICATION; ENDOPLASMIC RETICULUM; HUMAN; LIGAND BINDING; LIPOPHILICITY; MEDICINAL CHEMISTRY; NEUROPATHIC PAIN; NONHUMAN; PAIN; PHARMACOPHORE; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANALGESICS; ANIMALS; DRUG DISCOVERY; HUMANS; MOLECULAR SEQUENCE DATA; PAIN; RECEPTORS, SIGMA;

EID: 84905510106     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.54     Document Type: Review

References (118)

1. Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet 377, 2226-2235 (2011
2. Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health 11, 770 (2011
3. Mao J, Gold MS, Backonja M. Combination drug therapy for chronic pain: A call for more clinical studies. J. Pain 12, 157-166 (2011
4. Zamanillo D, Romero L, Merlos M, Vela JM. Sigma 1 receptor: A new therapeutic target for pain. Eur. J. Pharmacol. 716, 78-93 (2013
5. Martin WR, Eades CG, Thompson JA et al. The effects of morphine-And nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197, 517-532 (1976
6. Narayanan S, Bhat R, Mesangeau C et al. Early development of sigma-receptor ligands. Future Med. Chem. 3, 79-94 (2011
7. Hellewell SB, Bruce A, Feinstein G et al. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: Characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 268, 9-18 (1994
8. Zamanillo D, Portillo-Salido E, Vela JM, Romero L. Sigma 1 receptor chaperone: Pharmacology and therapeutic perspective. In: Therapeutic Targets. Botana LM, Loza M (Eds). John Wiley & Sons, NJ, USA, 225-278 (2012
9. Cobos EJ, Baeyens JM, Del Pozo E. Phenytoin differentially modulates the affinity of agonist and antagonist ligands for sigma 1 receptors of guinea pig brain. Synapse 55, 192-195 (2005
10. Laboratorios del Dr Esteve S.A. Method to identify ligands for sigma-1 receptors. WO2013104648 (2013
11. Niso M, Abate C, Ferorelli S et al. Investigation of s receptors agonist/antagonist activity through N-(6-methoxytetralin-1-yl)-And N-(6-methoxynaphthalen-1-yl) alkyl derivatives of polymethylpiperidines. Bioorg. Med. Chem. 7, 1865-1869 (2013
12. Mach RH, Zeng C, Hawkins WG. The s2 receptor: A novel protein for the imaging and treatment of cancer. J. Med. Chem. 56, 7137-7160 (2013
13. Banister S, Kassiou M. The therapeutic potential of sigma (s) receptors for the treatment of central nervous system diseases: Evaluation of the evidence. Curr. Pharm. Design 18, 884-901 (2012
14. Hanner M, Moebius FF, Flandorfer A et al. Purification, molecular cloning, and expression of the mammalian sigma-1 binding site. Proc. Natl Acad. Sci. USA 93, 8072-8077 (1996
15. Xu J, Zeng C, Chu W et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat. Commun. 2, 380 (2011
16. Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol. Ther. 124, 195-206 (2009
17. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ERmitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131, 596-610 (2007
18. Su TP, Hayashi T, Maurice T et al. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol. Sci. 31, 557-566 (2010
19. Hayashi T, Tsai SY, Mori T et al. Targeting ligandoperated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin. Ther. Targets 15, 557-577 (2011
20. Balasuriya D, Stewart AP, Edwardson JM. The s-1 receptor interacts directly with GluN1 but not GluN2A in the GluN1/GluN2A NMDA receptor. J. Neurosci., 33, 18219-18224 (2013
21. Carnally SM, Johannessen M, Henderson RM et al. Demonstration of a direct interaction between sigma-1 receptors and acid-sensing ion channels. Biophys. J. 98, 1182-1191 (2010
22. Kim FJ, Kovalyshyn I, Burgman M et al. Sigma 1 receptor modulation of G-protein-coupled receptor signaling: Potentiation of opioid transduction independent from receptor binding. Mol. Pharmacol. 77, 695-703 (2010
23. Kourrich S, Hayashi T, Chuang JY et al. Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine. Cell 152, 236-247 (2013
24. Navarro G, Moreno E, Aymerich M et al. Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc Natl Acad Sci USA 107, 18676-18681 (2010
25. Navarro G, Moreno E, Bonaventura J et al. Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers. PLoS ONE 8, e61245 (2013
26. Tchedre KT, Huang RQ, Dibas A et al. Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction. Invest. Ophthalmol. Vis. Sci. 49, 4993-5002 (2008
27. Palmer CP, Mahen R, Schnell E et al. Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. Cancer Res. 67, 11166-11175 (2007
28. Brune S, Pricl S, Wünsch B. Structure of the s1 receptor and its ligand binding site. J. Med. Chem. 56, 9809-9819 (2013
29. Aydar E, Palmer CP, Klyachko VA, Jackson MB. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34, 399-410 (2002
30. Wu, Z.; Bowen, W. D. Role of sigma-1 receptor C-Terminal segment in inositol 1, 4, 5-Trisphosphate receptor activation: Constitutive enhancement of calcium signaling in MCF-7 tumor cells. J. Biol. Chem. 283, 28198-28215 (2008
31. Chen Y, Hajipour AR, Sievert K et al. Characterization of the cocaine binding site on the sigma-1 receptor. Biochemistry 46, 3532-3542 (2007
32. Pal A, Chu UB, Ramachandran S et al. Juxtaposition of the steroid binding domain-like I and II regions constitutes a ligand binding site in the s-1 receptor. J. Biol. Chem. 283, 19646-19656 (2008
33. Fontanilla D, Hajipour AR, Pal A et al. Probing the steroid binding domain-like I (SBDLI) of the sigma-1 receptor binding site using N-substituted photoaffinity labels. Biochemistry 47, 7205-7217 (2008
34. Yamamoto H, Miura R, Yamamoto T et al. Amino acid residues in the transmembrane domain of the type 1 sigma receptor critical for ligand binding. FEBS Lett. 445, 19-22 (1999
35. Seth P, Ganapathy ME, Conway SJ et al. Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand binding domain of the receptor. Biochim. Biophys. Acta 1540, 59-67 (2001
36. Ortega-Roldan JL, Ossa F, Schnell JR. Characterization of the human sigma-1 receptor chaperone domain structure and binding immunoglobulin protein (BIP) interactions. J. Biol. Chem. 29, 21448-21457 (2013
37. Chu UB, Ramachandran S, Hajipur A, Ruoho AE. Photoaffinity labelling of the sigma-1 receptor with N-[3-(4-nitrophenyl)propyl]-N-dodecylamine: Evidence of receptor dimers. Biochemistry 52, 859-868 (2013
38. Ruoho AE, Chu UB, Ramachandran S et al. The ligand binding region of the sigma-1 receptor: Studies utilizing photoaffinity probes, sphingosine and N-Alkylamines. Curr. Pharm. Des. 18, 920-929 (2012
39. Glennon RA, Ablordeppey SA, Ismaiel AM et al. Structural features important for s1 receptor binding. J. Med. Chem. 37, 1214-1219 (1994
40. Laggner C, Schieferer C, Fiechtner B et al. Discovery of high-Affinity ligands of s1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening. J. Med. Chem. 48, 4754-4764 (2005
41. Zampieri D, Mamolo MG, Laurini E et al. Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma (1) receptor ligands based on a series of substituted benzo-[d]oxazol-2(3H)-one derivatives. J. Med. Chem. 52, 5380-5393 (2009
42. Banister SD, Manoli M, Doddareddy MR et al. A s1 receptor pharmacophore derived from a series of N-substituted 4-Azahexacyclo[5.4.1.02, 6.03, 10.05, 9.08, 11] dodecan-3-ols (AHDs). Bioorg. Med. Chem. Lett. 22, 6053-6058 (2012
43. Caballero J, Zilocchi S, Tiznado W et al. Models of the pharmacophoric pattern and affinity trend of methyl 2-(aminomethyl)-1-phenylcyclopropane-1- carboxylate derivatives as s1 ligands. Mol. Simul. 38, 227-235 (2012
44. Laurini E Col VD Mamolo MG et al. Homology model and docking based virtual screening for ligands of the s1 receptor. ACS Med. Chem. Lett. 2, 834-839 (2011
45. Laurini E, Marson D, Dal Col V et al. Another brick in the wall. Validation of the s1 receptor 3D model by computerassisted design, synthesis, and activity of new s1 ligands. Mol. Pharm. 9, 3107-3126 (2012
46. Rossi D, Pedrali A, Gaggeri R et al. Chemical, pharmacological, and in vitro metabolic stability studies on enantiomerically pure RC-33 compounds: Promising neuroprotective agents acting as s1 receptor agonists. Chem. Med. Chem. 8, 1514-1527 (2013
47. Geldenhuys WJ, Novotny, N, Malan SF et al. 3D-QSAR and docking studies of pentacycloundecylamines at the sigma-1 (s1) receptor. Bioorg. Med. Chem. Lett. 223, 1707-1711 (2013
48. Guo L, Zhao J, Jin G et al. SKF83959 is a potent allosteric modulator of sigma-1 receptor. Mol. Pharm. 83, 577-586 (2013
49. Veinberg G, Vorona M, Zvejniece L et al. Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-Acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor. Bioorg. Med. Chem. 21, 2764-2771 (2013
50. Ohsawa M, Carlsson A, Asato M et al. The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system. Mol. Pain 7, 85 (2011
51. M's Science Corp.: Sigma ligands for neuronal regeneration and functional recovery. WO2007053580 (2007
52. Fujimoto M, Hayashi T, Urfer R et al. Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor. Synapse 66, 630-639 (2012
53. Vamvakides A. New sigma(s)-receptorligands with antiapoptotic and/or pro-Apoptotic properties over cellular biochemical mechanisms, with neuroprotective, anti-cancer, anti-metastatic and anti-(chronic) inflammatory action. WO2008087458 (2008
54. Villard V, Espallergues J, Keller E et al. Anti-Amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (s1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J. Psychopharm. 25, 1101-1117 (2011
55. Rossi D, Marra A, Picconi P et al. Identification of RC-33 as a potent and selective s1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: GScale synthesis, physicochemical characterization and in vitro metabolic stability. Bioorg. Med. Chem. 21, 2577-2586 (2013
56. Mancuso R, Olivan S, Rando A et al. Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics 9, 814-826 (2012
57. Bhuiyan MS, Tagashira H, Fukunaga K. Crucial interactions between selective serotonin uptake inhibitors and sigma-1 receptor in heart failure. J. Pharmacol. Sci. 121, 177-184 (2013
58. Thomson Reuters Integrity: Htpps://integrity.thomsonpharma. com/integrity/xmlxsl/
59. Robson MJ, Noorbakhsh B, Seminerio MJ, Matsumoto RR. Sigma-1 receptors: Potential targets for the treatment of substance abuse. Curr. Pharm. Des. 18, 902-919 (2012
60. van Waarde A, Rybczynska AA, Ramakrishnan N et al. Sigma receptors in oncology: Therapeutic and diagnostic applications of sigma ligands. Curr. Pharm. Des. 16, 3519-3537 (2010
61. Chien CC, Pasternak GW. Sigma antagonists potentiate opioid analgesia in rats. Neurosci. Lett. 190, 137-139 (1995
62. Langa F, Codony X, Tovar V et al. Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice. Eur. J. Neurosci. 18, 2188-2196 (2003
63. Diaz JL, Zamanillo D, Corbera J et al. Selective sigma-1 (sigma1) receptor antagonists: Emerging target for the treatment of neuropathic pain. Cent. Nerv. Syst. Agents Med. Chem. 9, 172-183 (2009
64. de la Puente B, Nadal X, Portillo-Salido E et al. Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain 145, 294-303 (2009
65. Entrena JM, Cobos EJ, Nieto FR et al. Sigma-1 receptors are essential for capsaicin-induced mechanical hypersensitivity: Studies with selective sigma-1 ligands and sigma-1 knockout mice. Pain 143, 252-261 (2009
66. Cendan CM, Pujalte JM, Portillo-Salido E et al. Formalininduced pain is reduced in sigma-1 receptor knockout mice. Eur. J. Pharmacol. 511, 73-74, (2005
67. Nieto FR, Cendan CM, Sánchez-Fernández C et al. Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice. J. Pain 13, 1107-1121 (2012
68. Gonzαlez-Cano R, Merlos M, Baeyens JM Cendαn CM. s1 receptors are involved in the visceral pain induced by intracolonic administration of capsaicin in mice. Anesthesiology 118, 691-700 (2013
69. Kim HW, Kwon YB, Roh DH et al. Intrathecal treatment with sigma-1 receptor antagonists reduces formalininduced phosphorylation of NMDA receptor subunit 1 and the second phase of formalin test in mice. Br. J. Pharmacol. 148, 490-498 (2006
70. Roh DH, Kim HW, Yoon SY et al. Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain. Anesthesiology 109, 879-889 (2008
71. Son JS, Kwon YB. Sigma-1 receptor antagonist BD1047 reduces allodynia and spinal ERK phosphorylation following chronic compression of dorsal root ganglion in rats. Korean. J. Physiol. Pharmacol. 14, 359-364 (2010
72. Kwon YB, Jeong YC, Kwon JK et al. The antinociceptive effect of sigma-1 receptor antagonist, BD1047, in a capsaicin induced headache model in rats. Korean. J. Physiol. Pharmacol. 13, 425-429 (2009
73. Moon JY, Roh DH, Yoon SY et al. Sigma-1 receptormediated increase in spinal p38 MAPK phosphorylation leads to the induction of mechanical allodynia in mice and neuropathic rats. Exp. Neurol. 247, 383-391 (2013
74. Dableh LJ, Henry JL. Progesterone prevents development of neuropathic pain in a rat model: Timing and duration of treatment are critical. J. Pain Res. 4, 91-101 (2011
75. Kotagale NR, Shirbhate SH, Shukla P, Ugale RR. Agmatine attenuates neuropathic pain in sciatic nerve ligated rats: Modulation by hippocampal sigma receptors. Eur. J. Pharmacol. 714, 424-431 (2013
76. Dénaz JL, Cuberes R, Berrocal J et al. Synthesis and biological evaluation of the 1-Arylpyrazole class of s1 receptor antagonists: Identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine (S1RA, E-52862). J. Med. Chem. 55, 8211-8224 (2012
77. Romero L, Zamanillo D, Nadal X et al. Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. Br. J. Pharmacol. 166, 2289-2306 (2012
78. Bura AS, Guegan T, Zamanillo D et al. Operant selfadministration of a sigma ligand improves nociceptive and emotional manifestations of neuropathic pain. Eur. J. Pain. 17, 832-843 (2013
79. Vidal-Torres A, de la Puente B, Rocasalbas M et al. Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effects. Eur. J. Pharmacol. 711, 63-72 (2013
80. Sαnchez-Fernαndez C, Nieto FR, Gonzαlez-Cano R et al. Potentiation of morphine-induced mechanical antinociception by s1 receptor inhibition: Role of peripheral s1 receptors. Neuropharmacology 70, 348-358 (2013
81. Abadias M, Escriche M, Vaqué A et al. Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies. Br. J. Clin. Pharmacol. 75, 103-117 (2013
82. Esteve. www.esteve.es
83. Wünsch B. The s1 receptor antagonist S1RA is a promising candidate for the treatment of neurogenic pain. J. Med. Chem. 55, 8209-8210 (2012
84. Neubert J. Assessment of the sigma-1 receptor antagonist (S1RA): A model approach for preclinical analgesic drug discovery. Eur. J. Pain. 17, 789-790 (2013
85. Manglik A, Kruse AC, Kobilka TS et al. Crystal structure of the opioid receptor bound to a morphinan antagonist. Nature 485, 321-326 (2012
86. Corbera J, Vaño D, Martínez D et al. A medicinal chemistry guided approach to selective and drug-like sigma 1 ligands. Chem. Med. Chem. 1, 140-154 (2006
87. Waring MJ. Lipophilicity in drug discovery. Expert Opin. Drug Discov. 5, 235-248 (2010
88. Ferorelli S, Abate C, Pedone MP et al. Synthesis and binding assays of novel 3, 3-dimethylpiperidine derivatives with various lipophilicities as s1 receptor ligands. Bioorg. Med. Chem. 19, 7612-7623 (2011
89. Laurini E, Dal Col V, Wünsch B, Pricl S. Analysis of the molecular interactions of the potent analgesic S1RA with the s1 receptor. Bioorg. Med. Chem. Lett. 23, 2868-2871 (2013
90. Marrazzo A, Parenti C, Scavo V et al. In vivo evaluation of (+)-MR200 as a new selective sigma ligand modulating MOP, DOP and KOP supraspinal analgesia. Life Sci. 78, 2449-2453 (2006
91. Marrazzo A, Cobos EJ, Parenti C et al. Novel potent and selective s ligands: Evaluation of their agonist and antagonist properties. J. Med. Chem. 54, 3669-3673 (2011
92. Parent C, Marrazzo A, Aricò G et al. Effects of a selective sigma 1 antagonist compound on inflammatory pain. Inflammation 37(1), 261-266 (2013
93. Díaz JL, Christmann U, Fernández A et al. Synthesis and biological evaluation of a new series of hexahydro-2Hpyrano 3, 2-c]quinolines as novel selective s1 receptor ligands. J. Med. Chem. 56, 3656-3665 (2013
94. Utech T, Kfhler J, Buschmann H et al. Synthesis and pharmacological evaluation of a potent and selective s1 receptor antagonist with high antiallodynic activity. Arch. Pharm. Chem. Life Sci. 344, 415-421 (2011
95. Utech T, Kfhler J, Wünsch B. Synthesis of 4-(aminoalkyl) substituted 1, 3-dioxanes as potent NMDA and s receptor antagonists. Eur. J. Med. Chem. 46, 2157-2169 (2011
96. Wiese C, Maestrup EG, Schepmann D et al. Pharmacological and metabolic characterisation of the potent s1 receptor ligand 10-benzyl-3-methoxy-3H- spiro[[2]benzofuran-1, 4-piperidine]. J. Pharm. Pharmacology 61, 631-640 (2009
97. Schldger T, Schepmann D, Lehmkuhl K et al. Combination of two pharmacophoric systems: Synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high s1 receptor affinity. J. Med. Chem. 54, 6704-6713 (2011
98. Oberdorf C, Schepmann D, Vela JM et al. Thiophene bioisosteres of spirocyclic s receptor ligands. 1. N-Substituted spiro[piperidine-4, 4'-Thieno[3, 2-c]pyrans]. J. Med. Chem. 51, 6531-6537 (2008
99. Oberdorf C, Schepmann D, Vela JM et al. Thiophene bioisosteres of spirocyclic s receptor ligands: Relationships between substitution pattern and s receptor affinity. J. Med. Chem. 55, 5350-5360 (2012
100. Meyer C, Schepmann D, Yanagisawa S et al. Pd-Catalyzed direct C-H bond functionalization of spirocyclic s1 ligands: Generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the s1 receptor. J. Med. Chem. 55, 8047-8065 (2012
101. Meyer C, Neue B, Schepmann D et al. Improvement of s1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones Bioorg. Med. Chem. 21, 1844-1856 (2013
102. Wünsch B. Pharmacophore models and development of spirocyclic ligands for s1 receptors. Curr. Pharm. Des. 18, 930-937 (2012
103. Riganas S, Papanastasiou J, Foscolos GB et al. New adamantane derivatives with sigma affinity and antiproliferative activity. Med. Chem. 8, 569-586 (2012
104. Riganas S, Papanastasiou J, Foscolos GB et al. Synthesis, s1, s2-receptors binding affinity and antiproliferative action of new C1-substituted adamantanes. Bioorg. Med. Chem. 20, 3323-3331 (2012
105. Riganas S, Papanastasiou J, Foscolos GB et al. New adamantane phenylalkylamines with s-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain. J. Med. Chem. 55, 10241-10261 (2012
106. Mochida Pharmaceutical Co. Ltd: Therapeutic agent for pain. WO2006118307 (2006
107. 8th AFMC International Medicinal Chemistry Symposium" Frontier of Medicinal Science". 29 November-2 December, Tokyo, Japan, Abstract 2P-132 (2011
108. Collina S, Gaggeri R, Marra A et al. Sigma receptor modulators: A patent review. Expert Opin. Ther. Pat. 23, 597-613 (2013
109. Seminerio MJ, Hansen R, Kaushal N et al. The evaluation of AZ66, an optimized sigma receptor antagonist, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice. Int. J. Neuropsychopharm. 16, 1033-1044 (2013
110. Stavitskaya L, Seminerio MJ, Healy JR et al. Effect of ringconstrained phenylpropyloxyethylamines on sigma receptors. Bioorg. Med. Chem. 21, 4923-4927 (2013
111. Sadeghzadeh M, Sheibani S, Ghandi M et al. Synthesis and receptor binding studies of novel 4, 4-disubstituted arylalkyl/arylalkylsulfonyl piperazine and piperidine-based derivatives as a new class of s1 ligands. Eur. J. Med. Chem. 64, 488-497 (2013
112. Yu LF, Zhang HK, Gunosewoyo H, Kozikowski AP. From α4β2 nicotinic ligands to the discovery of s1 receptor ligands: Pharmacophore analysis and rational design. ACS. Med. Chem. Lett. 3, 1054-1058 (2012
113. Bhat R, Fishback JA, Matsumoto RR et al. Structure activity relationship study of benzo[d]thiazol-2(3H)one based s receptor ligands. Bioorg. Med. Chem. Lett. 23, 5011-5013 (2013
114. James ML, Shen B, Zavaleta CL et al. New positron emission tomography (PET) radioligand for imaging s1 receptors in living subjects. J. Med. Chem. 55, 8272-8282 (2012
115. Banister SD, Manoli M, Barron ML et al. N-substituted 8-Aminopentacyclo[5.4.0.02, 6.03, 10.05, 9]undecanes as s receptor ligands with potential neuroprotective effects. Bioorg. Med. Chem. 21, 6038-6052 (2013
116. Banister SD, Rendina LM, Kassiou M. 7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s2) receptor ligands. Bioorg. Med. Chem. Lett. 22, 4059-4063 (2012
117. Moussa IA, Banister SD, Manoli M et al. Exploration of ring size in a series of cyclic vicinal diamines with s1 receptor affinity. Bioorg. Med. Chem. Lett. 22, 5493-5497 (2012
118. Laboratorios del Dr. Esteve, S.A. Pyrazolo[3, 4-d]pyrimidine compounds, their preparation and use as sigma ligands. WO2013010950 (2013.